neoprobe news

IMMEDIATE RELEASE **March 11, 2010**

CONTACTS:
Brent Larson,
Vice President / CFO
614 822 2330

Tim Ryan,
The Shoreham Group
212 242 7777

NEOPROBE TO HOLD LYMPHOSEEK UPDATE CALL

Conference Call Scheduled for 8:30 a.m. tomorrow, Friday, March 12, 2010

DUBLIN, OHIO – March 11, 2010 - Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it will hold a conference call tomorrow, Friday, March 12, 2010 to discuss the positive outcomes of a recent meeting with the United States Food and Drug Administration (FDA) regarding the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®, and the development pathway for a new drug application for Lymphoseek. The Phase 3 clinical study (NEO3-05) was conducted in subjects diagnosed with either breast cancer or melanoma.

Neoprobe's President and CEO, David Bupp, Vice President, Pharmaceutical Research and Clinical Development, Frederick Cope, Ph.D., and Vice President, Regulatory Affairs and Quality Assurance, Rodger Brown, will discuss the NEO3-05 results and FDA meeting results during a conference call scheduled for 8:30 AM EST, Friday, March 12, 2010.

The conference call can be accessed as follows:

Conference Call Information			
TO PARTICIPATE LIVE:		**TO LISTEN TO A REPLAY:**	
Date:	Mar. 12, 2010	Available until:	Mar. 19, 2010
Time:	8:30 AM ET	Toll-free (U.S.) Dial in # :	(877) 660-6853
		International Dial in # :	(201) 612-7415
Toll-free (U.S.) Dial in # :	(877) 407-8031		
International Dial in # :	(201) 689-8031	Replay passcode:	
		Account #:	286
		Conference ID #:	346813

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com